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Many patients who present with Pseudomonas aeruginosa bacteremia have been previously exposed to anti-
biotics. To assess whether resistance of bacteremic strains to antipseudomonal antibiotics (piperacillin, cef-
tazidime, imipenem, ciprofloxacin, or aminoglycosides) is associated with previous exposure to these drugs,
a case-control study including 267 cases of P. aeruginosa bacteremia was conducted. Twenty-five percent of
the episodes had been preceded by the exposure to an antipseudomonal antibiotic. Eighty-one strains were
resistant to at least 1 antibiotic; 186 were susceptible to all drugs. Via univariate analysis, the risks of resistance
to ceftazidime and imipenem were found to be significantly associated with previous receipt of these agents.
Using multivariate analysis, exposure to any antipseudomonal antibiotic as a monotherapy was found to be
associated with an increased risk of subsequent resistance to itself (odds ratio, 2.5; ). Therefore,Pp .006
clinicians should avoid readministering previously prescribed antibiotics when initiating empiric therapies for
possible P. aeruginosa bacteremia, especially when they have been given as monotherapies.
Pseudomonas aeruginosa is a leading cause of nosocom-
ial bloodstream infections, ranking third among gram-
negative bacteria, after Escherichia coli and Klebsiella
species [1]. Despite improvement in recent years, the
prognosis of P. aeruginosa bacteremia remains poor,
with case-fatality rates of 20% [2–5]. Factors that
delay therapeutic improvements are the rapid course
of the disease, the scarcity of antibiotics with antipseu-
domonal activity, and the ease with which the bacte-
Received 9 April 2001; revised 11 July 2001; electronically published 24 October
2001.
Presented in part: European Congress of Clinical Microbiology and Infectious
Diseases, Stockholm, Sweden, 28–31 May 2000 (abstract Tu017).
Financial support: Swiss National Research Foundation (grants 3231-051940.97
and 3200-052189.97 [C.V.D.]).
a Present affiliation: Unilabs SA, Pl. Cornavin 12, Geneva, Switzerland (R.A.).
Reprints or correspondence: Dr. Christian van Delden, Dept. of Genetics and
Microbiology, Medical School of the University of Geneva, CMU, 9 av Champel,
CH-1211 Geneva 14, Switzerland (Christian.vandelden@medecine.unige.ch).
Clinical Infectious Diseases 2001; 33:1859–64
 2001 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2001/3311-0009$03.00
rium acquires new resistances during antibiotic ther-
apy [6]. As a result of this capacity to rapidly acquire
resistance mechanisms, P. aeruginosa bacteremia fre-
quently follows other infections treatment with antibiotic
regimen that include antipseudomonal drugs.
Because the symptoms of P. aeruginosa bacteremia
are nonspecific, the initial antibiotic therapy for pos-
sible P. aeruginosa bacteremia is almost always empir-
ical, with a pending identification of the responsible
pathogen and an unknown antibiotic resistance profile.
Inappropriate antibiotic treatment of bacteremia is as-
sociated with a significantly poorer outcome [7]. It is
therefore important to determine whether recent ex-
posure to antibiotics with antipseudomonal activity in-
creases the risk of resistance of bacteremic strains to
these agents [3]. Answering this question would help
clinicians choose the most adequate empirical treat-
ment in clinical situations that include P. aeruginosa
bacteremia as a possible cause.
We identified 267 P. aeruginosa bacteremic events
that occurred at a tertiary-care hospital and conducted
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a case-control study to determine whether recent exposure to
antibiotics with antipseudomonal activity was associated with
an increased risk of resistance toward these drugs.
PATIENTS AND METHODS
This study took place at the Geneva University Hospital, Swit-
zerland, a 1000-bed tertiary-care teaching center that serves as
a first-line medical center for an urban population of ∼400,000
inhabitants and as a referral center for a larger population
coming from both Switzerland and nearby France.
Study design. We used the microbiology laboratory da-
tabase of the hospital to identify all inpatients that had had 1
or several blood cultures positive for P. aeruginosa from 1 Jan-
uary 1989 through 31 December 1998. Medical records were
reviewed for information on demographic characteristics, clin-
ical presentation of bacteremia, primary site of P. aeruginosa
infection, underlying medical conditions, immunosuppression
at the time of bacteremia, invasive procedures, laboratory re-
sults of antibiotic susceptibility, and recent antibiotic treatment
including an agent with antipseudomonal activity. An “episode”
of P. aeruginosa bacteremia was defined as a positive blood
culture with this pathogen. “Previous monotherapy” was de-
fined as a therapy that started within 30 days before the positive
blood culture, included only 1 of the antipseudomonal anti-
biotics used in our institution (piperacillin, ceftazidime, imi-
penem, ciprofloxacin, gentamicin, and amikacin), was admin-
istered for 148 h, and was stopped !15 days before the
bacteremia. “Previous combination therapy” was defined as fol-
lows: treatment was initiated within 30 days and stopped !15
days before the positive blood culture; it included the concom-
itant use for 48 h of a b-lactam antibiotic, and either an
aminoglycoside or ciprofloxacin, or the combination cipro-
floxacin plus aminoglycoside, with an exposure to a single drug
for no more than 48 h. All other patterns of antibiotic exposure
were classed in the “no previous treatment” group. In a first
analysis, “cases” were defined as episodes of bacteremia caused
by a strain of P. aeruginosa resistant to at least 1 antipseu-
domonal antibiotic and “controls” as episodes involving strains
susceptible to all 6 antibiotics. Three categories of exposure
were examined: any previous combination therapy, any pre-
vious monotherapy, and no previous therapy. In subsequent
analyses, cases were episodes caused by a strain resistant to 1
specified antibiotic, and controls were episodes caused by a
strain susceptible to that same antibiotic; hence, bacteremic
strains resistant to 2 antibiotics contributed more than once
to these analyses. Patients were considered exposed if they had
received the specified antibiotic either as a monotherapy or as
an agent included in a combination therapy.
Microbiology. A minimum of 2 pairs of blood cultures
was performed at the time of presumed bacteremia. P. aeru-
ginosa was identified at the laboratory of clinical microbiology
via standard clinical microbiology methods [8]. Antimicrobial
susceptibility was determined by disk diffusion methods ac-
cording to the recommendations of the National Committee
for Clinical Laboratory Standards (NCCLS) [9]. An isolate was
considered susceptible, intermediate, or resistant according to
the criteria of the NCCLS. The isolates with intermediate sus-
ceptibility were classified as resistant for analysis. No molecular
typing was performed.
Statistical analysis. We calculated crude ORs and exact
95% CI to evaluate the potential relation between previous
antipseudomonal therapy and resistance of the bacteremic
strain. Two-tailed Fisher’s exact tests were used for the com-
parison of proportions.
Multiple logistic regression was used to assess whether having
received a previous monotherapy or combination therapy in-
cluding a specific antipseudomonal agent were independent risk
factors for resistance of the bacteremic isolate to that same
agent. Because data were scarce, observations corresponding to
all 6 antibiotics were pooled in a stratified model. Therefore,
each episode of bacteremia contributed 5 times to the model
(1 stratum per antibiotic); variance estimates were adjusted to
reflect the resulting dependence among observations. Previous
monotherapy and combination therapy were forced in the
model; we further considered independent variables with P !
in univariate logistic regression (data not shown). To limit.2
the risk of overfitting, no interaction terms were tested. Re-
gression analyses were performed by STATA version 6.0 (STATA
Corporation).
RESULTS
Characteristics of bacteremic episodes. During the study pe-
riod, 273 P. aeruginosa bacteremic episodes occurred in 267
patients. Computerized microbiological data and medical re-
cords were available for all patients. Four patients had 2 in-
dependent episodes of bloodstream infections separated by
14–69 days, and 1 person had 3 episodes over a period of 50
days. We report here on the 267 initial episodes of P. aeruginosa
bacteremia.
The overall incidence of P. aeruginosa bacteremia at the Ge-
neva University Hospital was 1 per 1000 admissions (range per
year, 0.63‰–1.45‰). P. aeruginosa bacteremia accounted for
5.4% (range, 3.7%–7.6%) of all bloodstream infections. The
mean age of the patients was 59 years (range, 1 day to 93 years;
SD, 22 years), and approximately two-thirds were men (table
1). At the time of bacteremia, 32% of patients were hospitalized
in acute-care and 14% in chronic-care medical services, 17%
were in surgical wards, and 37% were in intensive care units
(medical and surgical). The most common sites of primary
infection were the respiratory and the urinary tracts; no source
Table 1. Univariate associations of clinical characteristics with resistance of Pseudomonas aeru-






OR (95% CI) P
1 resistance
(cases; n p 81)
No resistance
(controls; n p 186)
Previous antipseudomonal therapya
No 201 (75.3) 55 146 — —
Yes 64 (24.0) 26 38 1.8 (0.96–3.4) .09
Monotherapy 54 (20.2) 22 32 1.8 (0.92–3.6) .07
Combination therapyb 10 (3.7) 4 6 1.8 (0.35–7.8) .47
Age, years
!65 132 (49.4) 44 88 — —
65 135 (50.6) 37 98 0.76 (0.43–1.3) .35
Sex
Male 195 (73.0) 59 136 — —
Female 72 (27.0) 22 50 1.0 (0.53–1.9) 1.0
Calendar time
1988–1992 126 (47.2) 27 99 — —
1993–1998 141 (52.8) 54 87 2.3 (1.3–4.1) .003
Ward
Medical acute care 84 (31.5) 18 66 — —
Other 183 (68.5) 63 120 1.9 (1.0–3.7) .03
Primary site(s) of infection
Unknown/other 142 (53.2) 38 104 — —
Respiratory 47 (17.6) 16 31 1.4 (0.64–3.0) .36
Urinary 46 (17.2) 20 26 2.1 (1.0–4.4) .04
Digestive 24 (9.0) 9 15 1.6 (0.58–4.4) .33
Vascular 17 (6.4) 3 14 0.59 (0.10–2.3) .56
Cutaneous 13 (4.9) 2 11 0.50 (0.05–2.4) .52
Clinical presentation
Fever/simple sepsis 183 (68.5) 48 135 — —
Severe sepsis 29 (10.9) 11 18 1.7 (0.68–4.2) .26
Shock 55 (20.6) 22 33 1.9 (0.94–3.7) .06
Underlying medical conditionc
No 34 (12.7) 11 23 — —
Yes 233 (87.3) 70 163 0.9 (0.39–2.2) .84
Immunological risk factor for infection
None of the following 203 (76.0) 64 139 — —
Neutropenia 48 (18.0) 10 38 0.57 (0.24–1.3) .16
Steroid treatment 18 (6.7) 7 11 1.4 (0.43–4.1) .60
Invasive procedures
None of the following 48 (18.0) 7 41 — —
Vascular catheter 205 (76.8) 68 137 2.9 (1.2–8.1) .01
Urinary catheter 150 (56.2) 50 100 2.9 (1.2–8.3) .02
Intubation 101 (37.8) 32 69 2.7 (1.0–7.5) .03
Drainage tube 57 (21.3) 17 40 2.5 (0.86–7.8) .10
Parenteral nutrition 38 (14.2) 14 24 3.4 (1.1–11.3) .02
Other 95 (35.6) 31 64 2.8 (1.1–7.8) .02
a Includes ceftazidime, piperacillin, imipenem, ciprofloxacin, an aminoglycoside, or some combination of these; 2 patients
had received a combination therapy with 2 antipseudomonal agents preceded or followed by a monotherapy with a third
agent.
b Two patients who had received monotherapy followed by combination therapy including other drugs were classified as
having received combination therapy.
c Malignancy, AIDS, diabetes, pancreatitis, respiratory dysfunction, heart disease, renal failure, severe nonpseudomonal
infection, or severe trauma.
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Table 2. Univariate analysis of therapies, including ceftazi-
dime, piperacillin, imipenem, ciprofloxacin, and aminoglycosides,
as risk factors for antibiotic-specific resistance in 267 bacteremic













Yes 3 5 —
No 13 246 11.4 (1.6–64.7) .008
Piperacillina
Yes 3 6 —
No 26 231 4.4 (0.67–22.1) .06
Imipenema
Yes 11 25 —
No 30 186 2.7 (1.1–6.5) .02
Ciprofloxacin
Yes 0 9 —
No 15 243 0.0 (0.0–9.1) 1.0
Aminoglycoside
Yes 6 26 —
No 37 198 1.2 (0.39–3.4) .61
a One isolate was not tested against piperacillin, and 15 were not tested
against imipenem.
of bacteremia could be identified in about half the patients.
Severe sepsis was the initial manifestation of bloodstream in-
fection in 11% of episodes and shock in 22%. Approximately
233 (90%) of 267 patients had severe underlying medical con-
ditions: 91, malignancy (34%); 69, heart disease (26%); 58,
respiratory dysfunction (22%); 51, nonpseudomonal severe in-
fection (19%); 48, renal failure (18%); 29, diabetes (11%); 16,
AIDS (6%); 14, severe trauma (5%); and 12, pancreatitis (4%).
Immunosuppression was documented in 64 patients (24%) and
invasive procedure that increased the risk of bacteremia in 219
(82%).
Sixty-six patients (24.7%) had been exposed to an antibiotic
therapy active against P. aeruginosa (monotherapy, ;np 54
combination therapy, ; monotherapy followed by a com-np 8
bination therapy with 2 other agents, ; table 1) beforenp 2
the bacteremic event. Of these regimens, 36 included imipenem;
9, piperacillin; 9, ciprofloxacin; 8, ceftazidime; and 32, an ami-
noglycoside (table 2). Of the 267 P. aeruginosa blood isolates,
15 were not tested for susceptibility to imipenem and 1 isolate
was not tested for susceptibility to piperacillin. A total of 186
blood isolates (70%) were susceptible to all tested antibiotics,
35 (13%) were resistant to 1 antibiotic, 27 (10%) to 2 anti-
biotics, and 19 (7%) to 3 antibiotics. Forty-three isolates
(16%) were resistant to an aminoglycoside (gentamicin or ami-
kacin), 41 (15%) to imipenem, 29 (11%) to piperacillin, 16
(6%) to ceftazidime, and 15 (6%) to ciprofloxacin.
Univariate risk factors for resistance to 1 antipseudo-
monal agent. Patients who had been exposed to previous
therapy including an antipseudomonal agent were marginally
more likely to have experienced a P. aeruginosa bloodstream
infection with a strain resistant to 1 of the study antibiotics
than patient who had not been previously exposed (OR, 1.8;
95% CI, 1.0–3.4; ; table 1). Previous exposure to aPp .06
monotherapy was marginally associated with an increased risk
of resistance (OR, 1.8; 95% CI, 0.92–3.6; ). No statis-Pp .07
tically significant association was found between a previous
combination therapy and risk of resistance (OR, 1.8; 95% CI,
0.35–7.8; ). Bacteremia experienced between 1993 andPp .47
1998, hospitalization on other units than the acute-care medical
services, urinary source of infection, septic shock as clinical
mode of presentation ( ), and having experienced anPp .06
invasive procedure (except a drainage tube) were other factors
significantly associated with resistance to 1 antibiotic.
Crude risk of resistance to an antibiotic after exposure to
that same antibiotic. In univariate analysis, we did not at-
tempt to distinguish between situations where an antibiotic had
been received as a monotherapy or as part of a combination
therapy (too few patients had received any specific antibiotic
as part of a combination therapy). Previous exposure to cef-
tazidime was significantly associated with an increased risk of
resistance of the bacteremic isolate toward this antibiotic (OR,
11.4; 95% CI, 1.6–64.7; ; table 2). Similarly, previousPp .008
treatment with imipenem was significantly associated with an
increased risk of resistance toward itself (OR, 2.7; 95% CI,
1.1–6.5; ), and previous exposure to piperacillin wasPp .02
marginally associated with an increased risk of resistance (OR,
4.4; 95% CI, 0.67–22.1; ). In contrast, previous expo-Pp .06
sure to ciprofloxacin or an aminoglycoside was not associated
with an increased risk of resistance to themselves.
Average adjusted risk of resistance to an antibiotic after
exposure to that same antibiotic. In multivariate analysis
stratified for antipseudomonal agents, previous monotherapy
with an antipseudomonal antibiotic was independently asso-
ciated with an increased risk of subsequent resistance of the
bacteremic strain to that antibiotic (OR, 2.5; 95% CI, 1.3–4.8;
; table 3). The risk of subsequent resistance was notPp .006
significantly increased among patients who had received a com-
bination therapy (OR, 1.8; 95% CI, 0.55–5.6; ). How-Pp .34
ever, no significant difference was observed between combi-
nation therapies and monotherapies in terms of independent
risk of subsequent resistance (OR, 0.70; 95% CI, 0.20–2.53;
). Finally, severe sepsis or shock as the primary man-Pp .59
ifestation of bacteremia was marginally associated with an in-
creased risk of resistance after controlling for previous antibiotic
therapy.
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Table 3. Multivariate association, averaged across antipseu-
domonal agents, of previous exposure to an agent, and resistance






the agent 2.5 (1.3–4.8) .006
Previous combination therapy
including the agent 1.8 (0.55–5.6) .34
Severe sepsis or septic shock 1.6 (0.94–2.6) .08
NOTE. Stratified logistic regression analysis in which each episode of
bacteremia contributed 5 times to the model (i.e., once per antipseudomonal
agent). Variance estimates were adjusted for the resulting dependence among
observations.
DISCUSSION
For clinicians who initiate empiric treatment in a clinical sit-
uation compatible with P. aeruginosa bacteremia, it is crucial
to assess the potential risk of a resistant causative bacterium.
In this retrospective study, 80 (30%) of 267 consecutive bac-
teremic isolates of P. aeruginosa were resistant to 1 antipseu-
domonal drug. Twenty-four percent of bacteremic episodes oc-
curred in patients who had been previously exposed to one or
several of these agents. Imipenem and aminoglycosides were
the most commonly administered antibiotics before the bac-
teremic event, and they were also the agents toward which the
bacteremic isolates were the most frequently resistant. In uni-
variate analysis, previous exposure to ceftazidime, piperacillin,
and imipenem were significantly or marginally associated with
an increased risk of resistance of the bacteremic isolate to them-
selves. After controlling for covariates, the average resistance
of the bacteremic strain to an antibiotic was 2.5 times more
likely when the patient had received previous monotherapy with
this antibiotic that when he had not been exposed to it. No
other treatment variable and none of the characteristics related
to patients and hospital environment independently predicted
resistance of the bacteremic isolate to an antipseudomonal
drug.
Exposure to antibiotics predisposes patients to colonization
with P. aeruginosa intrinsically resistant to these agents. P. aeru-
ginosa has also the capacity to rapidly become resistant during
the course of an antipseudomonal drug treatment [10]. There-
fore, previous therapies increase the risk of infections with se-
lected resistant P. aeruginosa isolates [7]. Moreover, through
the selection of resistant strains, previous exposure to antibi-
otics also increases the risk for the subsequent administration
of an inadequate antimicrobial treatment [11]. Finally, inade-
quate antibiotic treatments of P. aeruginosa bloodstream infec-
tions significantly increase the case-fatality rate [7, 11–13], pro-
long the hospital stay, and generate higher general costs [3, 14].
In this study, aminoglycosides were frequently administered
before the bacteremic event, and resistance toward these agents
was common among the bacteremic isolates. Nevertheless, pre-
vious exposure to aminoglycosides was not associated with an
increased risk of resistance. A possible explanation for this find-
ing is that resistance toward aminoglycosides in these patients
might not be due to a mechanism involving exposure to this
antimicrobial class, but rather to the induction of the MexXY-
OprM efflux system [15] by the exposure to other drugs. This
multidrug efflux system of P. aeruginosa is responsible for re-
sistance to aminoglycosides and is not only induced by exposure
to aminoglycosides, but also by exposure to other classes of
antibiotics such as macrolides or tetracycline [16].
The antibiotic ranking for postexposure risk of resistance dif-
fered in this study and that of Carmeli et al. [10]. In the latter
work, exposure to imipenem was associated with the highest risk
of resistance and ceftazidime with the lowest—findings the op-
posite of ours. Different study populations could explain these
differences. Indeed, the study of Carmeli et al. [10] focused not
only on bacteremic strains, but on both colonizing and invasive
isolates from various clinical sites. In addition, patients included
in the study by Carmeli et al. [10] were initially colonized with
organisms susceptible to the antibiotics to which subsequent
resistance was detected, and a minority of these resistant strains
were proven to have emerged from the original susceptible
clone. However, the study by Carmeli et al. [10] relied upon
an even smaller number of resistant isolates than ours (28 vs.
81). One limitation of our work is the absence of genotyping
of susceptible colonizing and resistant bacteremic strains, mak-
ing it impossible to distinguish new acquisition of resistance
by a previously susceptible strain from superinfection with a
genetically unrelated resistant strain.
Considerable debate exists concerning the usefulness of com-
bination therapies (usually the addition of an aminoglycosides
to a b-lactam antibiotic) in order to reduce the risk of emer-
gence of resistance in P. aeruginosa isolates [17–20]. In contrast
to previous monotherapies, previous combination therapies did
not predict subsequent resistance in this study. However neither
us nor Carmeli et al. [10] found a significant difference in risk
of resistance when monotherapy and combination therapies
were directly compared with each other. We studied one of the
largest retrospective series of P. aeruginosa bacteremia and had
almost no missing information. Nevertheless, our study lacked
power to identify differences in risk of resistance across anti-
biotics, as well as between monotherapy and combination
therapies.
In conclusion, bacteremic events that followed exposure to
antipseudomonal antibiotics were more likely to be due to re-
sistant P. aeruginosa strains. Therefore, when initiating an em-
piric treatment for a possible P. aeruginosa bacteremia, clini-
cians should avoid previously administered antibiotics, and in
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particular, they should avoid those that had been administered
as monotherapies.
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